Según estadísticas de la Alzheimer Association en Estados Unidos cada 65 segundos una persona desarrolla Alzheimer, una enfermedad que tiene a médicos e investigadores realizando estudios para desarrollar un medicamento o tratamientos que combatan este tipo de demencia que se desarrolla principalmente en personas mayores....
Dr Goldenberg shares how establishing a clinical trial centre for the vaccine was the “most interesting, challenging and rewarding” project of his career....
The use of clinical biomarkers obtained from cerebrospinal fluid (CSF) and magnetic resonance imaging may be effective for predicting risk for and aiding in the clinical decision-making of Alzheimer disease (AD) dementia, according to study findings published in JAMA Neurology....
High cumulative doses of zolpidem are associated with a greater risk for developing Alzheimer disease (AD) in elderly patients, according to a retrospective study published in the Journal of the American Geriatric Society....
It may be possible to grow old without developing Alzheimer’s disease pathology (ADP), although a wide range of very different types of protective factors are involved. A study published in JAMA Neurology looked at the differences in patterns of amyloid deposition and neurodegeneration that comprise ADP and found that, although challenging, “exceptional aging” without ADP is achievable.1...
Results from a systematic review and meta-analysis examining tools to detect depression in dementia show that tools incorporating collateral histories as well as a clinician interview with the patient, such as the Cornell Scale for Depression in Dementia (CSDD) or the Hamilton Depression Rating Scale (HDRS), have higher sensitivity for detecting depression, thus reducing false negatives....